RJFSA
ARRY

Raymond James Financial Services Advisors’s Array Biopharma Inc ARRY Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,572
Closed -$397K – 2978
2019
Q2 		$397K Sell
8,572
-8,221
-49% -$231K ﹤0.01% 2076
2019
Q1 		$409K Buy
16,793
+706
+4% +$14.7K ﹤0.01% 2018
2018
Q4 		$229K Sell
16,087
-1,085
-6% -$16.5K ﹤0.01% 2174
2018
Q3 		$261K Buy
17,172
+1,085
+7% +$16.6K ﹤0.01% 2363
2018
Q2 		$270K Sell
16,087
-12,269
-43% -$195K ﹤0.01% 2308
2018
Q1 		$463K Buy
28,356
+12,977
+84% +$208K ﹤0.01% 1767
2017
Q4 		$197K Sell
15,379
-114
-0.7% -$1.3K ﹤0.01% 2277
2017
Q3 		$191K Sell
15,493
-2,824
-15% -$26.2K ﹤0.01% 2294
2017
Q2 		$153K Buy
18,317
+7,661
+72% +$62.6K ﹤0.01% 2287
2017
Q1 		$95K Buy
+10,656
New +$113K ﹤0.01% 2268

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Raymond James Financial Services Advisors's ARRY Position: Q3 2019 in Review

Raymond James Financial Services Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 8,572 shares — an estimated $397K sold.

Raymond James Financial Services Advisors first reported a position in ARRY in Q1 2017 and held it in 10 quarters. The position peaked at $463K in Q1 2018. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Raymond James Financial Services Advisors reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 8,572 Array Biopharma Inc shares in Q3 2019, an estimated $397K.
  • Raymond James Financial Services Advisors first reported a position in Array Biopharma Inc in Q1 2017 and held it in 10 quarters.
  • Raymond James Financial Services Advisors's Array Biopharma Inc position peaked at $463K in Q1 2018.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2019, filed 7 Nov 2019.